{
  "report_rows": [
    {
      "kpi": "2Q26 adjusted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$1.31 vs. cons $1.28",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "2Q26 comparable sales growth",
      "prediction": "IN-LINE",
      "answer": "pred ~10.0% vs. cons 9.85%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "2Q26 Diabetes Care / CGM comparable sales growth",
      "prediction": "IN-LINE",
      "answer": "pred ~10.5% vs. cons 10.0%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY26 comparable sales-growth outlook",
      "prediction": "UNCHANGED",
      "answer": "guide ~7.0% midpoint vs. cons 7.0% (FY26)",
      "confidence": "HIGH"
    },
    {
      "kpi": "FY26 adjusted EPS outlook",
      "prediction": "UNCHANGED",
      "answer": "guide ~$5.48 midpoint vs. cons $5.50 (FY26)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Exact Sciences acquisition-related adjusted-EPS dilution",
      "prediction": "UNCHANGED",
      "answer": "guide ~$0.20 dilution vs. cons $0.20 dilution (FY26)",
      "confidence": "HIGH"
    }
  ],
  "day1_residual_pct": 2.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 1.0,
  "day5_path": "FADE",
  "day5_rationale": "~+2.5% day-1 residual vs. ~+1.0% five-day residual: a modest EPS beat and restored double-digit CGM growth should support the initial reaction, but unchanged FY26 EPS and sales outlook leaves the second-half acceleration embedded in out-period math rather than creating a material estimate-revision catalyst.",
  "day5_confidence": "MEDIUM"
}